Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.
The announcement, made on June 25, 2026, marks a significant step in broadening the adoption of precision cardiovascular medicine within community healthcare networks. Cardio Diagnostics stated that Epi+Gen CHD evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers. Both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, making them more accessible and convenient for patients.
This development is important because coronary heart disease remains a leading cause of death globally. Traditional diagnostic methods often involve invasive procedures or exposure to radiation, which can deter patients from seeking timely assessment. By offering noninvasive blood tests, Cardio Diagnostics aims to lower barriers to early detection and personalized management. The integration of these tests into Atlas Healthcare Physicians’ coverage could set a precedent for other independent physician associations and managed care organizations to follow, potentially expanding the reach of precision medicine.
For patients in the Los Angeles and Orange county areas, this means improved access to advanced cardiovascular risk assessment and diagnosis. The tests are ordered by physicians and require prior authorization, ensuring that they are used appropriately for eligible members. This targeted approach may help identify high-risk individuals earlier, allowing for interventions that could prevent heart attacks or other cardiac events.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that leverages a proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company’s mission is to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. For more information, the full press release is available at https://nnw.fm/EFQen.
It is important to note that certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially. For a detailed discussion of risk factors, refer to the Company’s filings with the SEC. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO.
